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divided by the duration of time in the data. A regression
model explained AUC as a function of rapid transition-
ing to insulin. A Cox model assessed the relationship
between the time to ﬁrst complication and AUC, rapid
transition to insulin and the number of modiﬁcations.
RESULTS: A total of 3137 patients satisﬁed all study
entry criteria; 1230 patients were initiated on diet and
exercise, 1756 on oral agents, and 151 on insulin. Demo-
graphics were comparable. Of patients initiated on diet
and exercise 66 switched to insulin in 2.4 months. In the
linear regression model explaining AUC (R2 = 0.185),
rapid transition to insulin was signiﬁcant (-0.19, p =
0.04) indicating that insulin sooner improves blood
glucose control. Of the 3137 patients, 954 encountered
complications. Time to ﬁrst complication was negatively
related to AUC (-0.04, p < 0.01) and rapid use of insulin
(-0.45, p < 0.01) with hazard ratios of 0.962 and 0.637
and positively related to the number of modiﬁcations
(0.08, p < 0.01) with a hazard ratio of 1.083. CON-
CLUSIONS: Initial or immediate transition to insulin
results in better blood glucose control that reduces the
onset of diabetes-related complications.
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OBJECTIVES: Pioglitazone (PIO), a thiazolidinedione, is
a member of a new class of oral antidiabetic agents 
targeted to treat insulin resistance, the major underlying
cause of type 2 diabetes mellitus. Insulin (INS) is believed
to be the “gold standard” for achieving optimal glycaemic
control. This study is aimed to compare both treatment
options with regard to metabolic control and effective-
ness under the conditions of daily practice. METHODS:
Prospective, controlled, non-randomized observational
study where patient selection, allocation to treatment and
dose was left at the physicians’ discretion. Quality stan-
dards included a central laboratory and a regular moni-
toring. Primary parameter was the change of HbA1C
compared to baseline (D HbA1C) where a difference of
<0.5% between both arms was set for deﬁning non-
inferiority. Analyses were performed under the perspec-
tive of the German Statutory Health Care System.
RESULTS: A total of 299 and 218 patients in whom PIO
or INS was started for insufﬁcient metabolic control were
treated for a mean duration of 26 weeks at 51 specialised
out-patient diabetic centres. Adjusted D HbA1C (-0.72),
PIO; (-0.42) INS) and adjusted D Fasting Plasma Glucose
-24.5mg/dl, PIO; -19.5mg/dl, INS) were observed.
Responder rates (adjusted D HbA1C ≥0.6%) were 54.9%
(PIO) and 37.2% (INS), respectively. Mean total treat-
ment costs were €1207 (PIO) and €1510 (INS) where
mean costs for antidiabetic medication and glucose self-
monitoring (dip-stick measurement) could be assessed as
€646 (PIO) and €774 (INS). Compared to INS, PIO
revealed to be more cost-effective (D HbA1C/€1000) in
the insulin resistant (ATP-III), younger (<64 years) and
more obese (BMI <30kg/m2) individuals with shorter
diabetes duration (<5 years). For INS a similar trend
could not be observed. CONCLUSIONS: PIO proved to
be non-inferior to INS treatment in terms of metabolic
control as well as cost-effectiveness. Targeting individual
patient proﬁles achieve best possible outcomes.
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OBJECTIVES: To compare pharmacy costs for patients
fulﬁlling HEDIS® for diabetes in an HMO disease man-
agement program (DDM) vs. those not in the program.
METHODS: We analyzed HMO paid drug costs among
1362 continuously enrolled GHP members with pre-
scription coverage who met HEDIS® criteria for diabetes
January 1, 2000 to December 31, 2001. We compared
patients in an opt-in “DDM” versus those not enrolled.
Multiple linear regression was used to control for the
impact of age and gender. RESULTS: Of 1362 patients
fulﬁlling criteria, 1273 (93.5%) were in DDM versus 
89 (6.5%) not in DDM. The DDM male/female ratio
(Program M/F = 52.4%/47.6% vs. Non-program M/F =
58.6%/41.4.1%, p = 0.07) was similar and those in DDM
were 1.9 years younger than non-DDM (56.0 vs. 57.9
years, p = 0.15). Mean pharmacy PMPM paid claims for
DDM vs. non-DDM patients was $92.24 ( STD = $99.18)
vs $143.98 (STD = $136.78), (t = 4.63, p < .0001). The
mean PMPM for DDM vs. non-DDM for insulin for
($20.17 Program vs. $15.49), other diabetes medications
($29.71 vs. $25.39) and diabetes supplies ($4.31 vs.
$5.77) were not statistically different. The mean PMPM
for non-diabetes medications for DDM patients was 
of $61.06 (STD = $81.91) vs, a mean PMPM of $123.34
(STD = $131.97). After controlling for age and gender,
this difference was statistically signiﬁcant (p < .0001).
CONCLUSIONS: We observed lower pharmacy costs for
non-diabetes medicines among DDM participants. These
data suggest that diabetes disease management is not nec-
essarily associated with an increase in pharmacy costs.
